Ultragenyx Pharma (RARE) Misses Q4 EPS by 3c

Ultragenyx Pharma (NASDAQ: RARE) reported Q4 EPS of ($1.75), $0.03 worse than the analyst estimate of ($1.72).

For earnings history and earnings-related data on Ultragenyx Pharma (RARE) click here.

You May Also Be Interested In

• Westinghouse said to seek over $50 billion valuation in planned IPO
• Amneal gets FDA approval for lanreotide injection, launches immediately
• Anthropic delays planned IPO from October to November - WSJ